Association Between Use of beta-Blockers and Prostate Cancer-Specific Survival: A Cohort Study of 3561 Prostate Cancer Patients with High-Risk or Metastatic Disease

作者：Grytli Helene Hartvedt; Fagerland Morten Wang; Fossa Sophie D; Tasken Kristin Austlid^*

来源：European Urology, 2014, 65(3): 635-641.

DOI：10.1016/j.eururo.2013.01.007

• ASA
• beta-Adrenergic receptor antagonist
• beta-Blocker
• Epidemiology
• High-risk prostate cancer
• Metastasis
• Norway
• Prostate cancer
• Prostate cancer-specific mortality
• Statin

Background: We recently reported reduced prostate cancer (PCa)-specific mortality for b-blocker users among patients receiving androgen-deprivation therapy in a health survey cohort including 655 PCa patients. Information on clinical characteristics was limited.
Objective: To assess the association between beta-blockers and PCa-specific mortality in a cohort of 3561 prostate cancer patients with high-risk or metastatic disease, and to address potential confounding from the use of statins or acetylsalicylic acid (ASA).
Design, setting, and participants: Clinical information from all men reported to the Cancer Registry of Norway with a PCa diagnosis between 2004 and 2009 (n = 24 571) was coupled with information on filled prescriptions between 2004 and 2011 from the Norwegian Prescription Database. Exclusion criteria were low- or intermediate-risk disease; planned radiotherapy or radical prostatectomy; initiation of beta-blocker, ASA, or statin use after diagnosis where applicable; missing information on baseline Gleason score, prostate-specific antigen level, T stage or performance status; and missing follow-up.
Outcome measurements and statistical analysis: Cox proportional hazards modelling and competing risk regression modelling were used to analyse the effects of beta-blocker use on all-cause and PCa-specific mortality, respectively. Differences between beta-blocker users and nonusers regarding baseline clinical characteristics were assessed by the Wilcoxon-Mann-Whitney U test, Pearson chi-square test, and Student t test.
Results and limitations: Median follow-up was 39 mo. beta-Blocker use was associated with reduced PCa mortality (adjusted subhazard ratio: 0.79; 95% confidence interval [CI], 0.68-0.91; p value: 0.001). The observed reduction in PCa mortality was independent of the use of statins or ASA. We observed no association with all-cause mortality (adjusted hazard ratio: 0.92; 95% CI, 0.83-1.02). The main limitations of the study were the observational study design and short follow-up.
Conclusions: beta-Blocker use was associated with reduced PCa-specific mortality in patients with high-risk or metastatic disease at the time of diagnosis. Our findings need validation from further observational studies.

• 出版日期2014-3